Finance

Lists
4015:TADAWUL
Jamjoom Pharmaceuticals Fctry Cmpny SJSC
SAR 137.20
+0.15%
(+0.20) 1D
Sep 10, 3:10:16 PM GMT+3  ·   SAR
All symbols
SymbolPriceChange% Change
Generating top insights for 4015...
Open
SAR 136.60
High
SAR 137.30
Low
SAR 136.30
Mkt. cap
9.60B
Avg. vol.
32.80K
Volume
9.43K
Dividend
3.06%
Quarterly dividend
SAR 1.05
Ex-dividend date
Aug 2, 2026
P/E ratio
19.98
52-wk high
SAR 165.30
52-wk low
SAR 125.00
EPS
SAR 6.87
Shares outstanding
29.31M
No. of employees
1K
Open
SAR 136.60
High
SAR 137.30
Low
SAR 136.30
Mkt. cap
9.60B
Avg. vol.
32.80K
Volume
9.43K
Dividend
3.06%
Quarterly dividend
SAR 1.05
Ex-dividend date
Aug 2, 2026
P/E ratio
19.98
52-wk high
SAR 165.30
52-wk low
SAR 125.00
EPS
SAR 6.87
Shares outstanding
29.31M
No. of employees
1K
About Jamjoom Pharmaceuticals Fctry Cmpny SJSC
CEO-
Employees1.13K
Founded1994
Headquarters-
SectorPharmaceutical industry
Websitejamjoompharma.com
Previous reportsAll values in SAR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in SAR
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
342.31M
304.57M
481.38M
445.31M
Cost of goods sold
133.77M
121.19M
171.00M
151.66M
Cost of revenue
133.77M
121.19M
171.00M
151.66M
Research and development expenses
9.47M
10.86M
9.40M
10.94M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
90.86M
110.53M
125.39M
139.66M
Operating expense
98.61M
111.72M
138.01M
147.65M
Total operating expenses
232.38M
232.91M
309.01M
299.32M
Operating income
109.92M
71.66M
172.38M
146.00M
Other non operating income
-
-1.17M
-
-
EBT including unusual items
113.34M
76.91M
174.94M
146.22M
EBT excluding unusual items
113.34M
77.01M
174.94M
146.22M
Income tax expense
6.67M
8.84M
6.73M
8.59M
Effective tax rate
5.89%
11.49%
3.85%
5.87%
Other operating expenses
-1.72M
-8.56M
3.22M
-2.95M
Net income
106.67M
68.07M
168.21M
137.63M
Net profit margin
31.16%
22.35%
34.94%
30.91%
Earnings per share
-
-
-
-
Interest and investment income
991.15K
784.73K
2.32M
1.36M
Interest expense
-353.59K
-
-1.54M
-954.23K
Net interest expenses
637.55K
784.73K
785.30K
408.85K
Depreciation and amortization charges
-
-
-
-
EBITDA
120.95M
82.25M
183.73M
157.44M
Gain or loss from assets sale
18.06K
8.39K
34.74K
1.30K
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps